The U.S. International Trade Commission (Commission or USITC) today determined there is a reasonable indication that a U.S. industry is materially injured due to imports of n-cyclohexylbenzothiazole-2-sulfenamide (CBS) from China that are allegedly sold in the United States at less than fair value and subsidized by the government of China.

Chairman David S. Johanson and Commissioners Jason E. Kearns and Amy A. Karpel voted in the affirmative.

As a result of the Commission’s affirmative determinations, the U.S. Department of Commerce will continue its investigations of imports of this product from China.

The Commission’s public report, N-Cyclohexylbenzothiazole-2-Sulfenamide (CBS) from China (Inv. Nos. 701-TA-797 and 731-TA-1793 (Preliminary), USITC Publication 5757, June 2026), will contain the views of the Commission and information developed during the investigations.

The report will be available on the USITC website by July 23, 2026.